| Ytd | -0.36% | |
| 1y | -9.08% |
| Open | 11.56 | Prev Close | 10.95 | Low | 11.09 | High | 11.56 | Mkt Cap | 55.35M |
| Vol | 1.81K | Avg Vol | 26.29K | EPS | -2.80 | P/E | -3.97 | Forward P/E | -1.17 |
| Beta | 0.48 | Short Ratio | 1.10 | Inst. Own | 2.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 11.43 | 200-d Avg | 11.57 | 1yr Est | 6.50 |
INKT News
NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage
MiNK advances agenT-797 across respiratory, oncology and immune disease studies while expanding its
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage
NEW YORK and LVIV, Ukraine, May 28, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics (NASDAQ: INKT), a cli
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage
MiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call Transcript
MiNK Therapeutics NASDAQ: INKT said it is advancing its off-the-shelf invariant natural killer T cel
Randomized Phase 2 trial initiated for agenT-797 in severe acute lung injury and respiratory distres
NEW YORK and LVIV, Ukraine, May 14, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage bio
iNKT therapy, agenT-797, delivers context-dependent immune reprogramming showing activation in cance
NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage
MiNK Therapeutics, Inc. (NASDAQ: INKT - Get Free Report) has received a consensus rating of "Hold" f
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stag
NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stag
MiNK Therapeutics, Inc. (INKT) Q4 2025 Earnings Call Transcript
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stag
MiNK Therapeutics, Inc. (NASDAQ: INKT - Get Free Report) was the target of a significant growth in s
Recent milestones include strategic collaboration with C-Further to advance PRAME-targeted iNKT cell
MiNK Therapeutics Inc. (NASDAQ: INKT) shares are down during Wednesday's premarket session, possibly
Domo Inc (DOMO) stock jumped 48.8% in pre-market trading after beating Q4 earnings expectations by 1
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnin
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterl
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 56.6% to settle at $19.10 on Friday.
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnin